靶向病毒核糖核蛋白的抗流感病毒药物研究进展  

Progress in research on anti-influenza virus drugs targeting viral ribonucleoprotein

作　　者：俞蕴嘉 张洋[1] 王伟[1] YU Yun-jia;ZHANG Yang;WANG Wei(Key Laboratory of Marine Drugs,Ministry of Education,School of Medicine and Pharmacy,Ocean University of China.Qingdao 266003,China)

机构地区：[1]中国海洋大学海洋药物教育部重点实验室医药学院

出　　处：《中国海洋药物》2019年第3期87-94,共8页Chinese Journal of Marine Drugs

基　　金：国家自然科学基金项目(81874320,81741146);国家自然科学基金-山东省联合基金项目(U1606403,U1706210);山东省自然基金项目(ZR2017MH013)资助

摘　　要：流行性感冒病毒所导致的人畜共患病长久以来威胁着人类的健康,但目前可用于临床的抗流感病毒药物十分有限,且逐渐出现了病毒耐药性的问题。因此,研究者们近来致力于探究新型抗流感药物靶点的发现,并期望针对新靶点设计疗效好且不易发生耐药的抗流感病毒药物。流感病毒核糖核蛋白具有不同毒株间保守性高,在病毒复制周期中作用广泛的特点,是设计开发新型抗流感药物的潜在靶点。本文对目前临床使用的抗流感药物靶点、核糖核蛋白的结构与功能及其相关药物的研究进展进行了综述,以期为新型抗流感药物的研发提供参考。The zoonotic disease flu caused by the influenza virus has long threatened human health,but there are very limited anti-influenza drugs available for clinical use,and the problem of virus resistance has gradually emerged.Therefore,researchers have recently been working on the discovery of new anti-influenza drug targets,and expecting to design novel anti-IAV drugs with good efficacy and low risk of inducing drug resistance.Influenza virus ribonucleoprotein has high conservativeness among different strains and plays a wide role in the replication cycle of influenza viruses.Thus,virus ribonucleoprotein could be a potential target for the design and development of novel anti-influenza drugs.This article is aimed to review the current research progress on the target of anti-IAV drugs in clinical,the structure and function of ribonucleoprotein and related drugs,so as to provide reference for the research and development of novel anti-influenza drugs.

关 键 词：流感病毒 核糖核蛋白 新靶点 抗病毒药物 天然产物 

分 类 号：R915[医药卫生—微生物与生化药学]